Leerink Partners analysts reiterated a Outperform rating on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) on January 13, 2026. Bristol-Myers Squibb Company PFD CONV 2…
Leerink Partners analysts reiterated a Outperform rating on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) on January 13, 2026.
Bristol-Myers Squibb Company PFD CONV 2 operates in the Healthcare sector. The stock currently trades at $936.80 with a market capitalization of $1,815,889,000,000.
Current market data
OTC · BMYMP
$400.00
Down: -$540.22 · -57.46%
Live quote updated
Keep reading
analyst ·
analyst ·
analyst ·
analyst ·
